Biteman Benjamin, Hassan Iram R, Walker Everald, Leedom Alexander J, Dunn Michael, Seta Francesca, Laniado-Schwartzman Michal, Gronert Karsten
Department of Pharmacology, New York Medical College, Basic Science Bldg., Valhalla, NY 10595, USA.
FASEB J. 2007 Jul;21(9):2257-66. doi: 10.1096/fj.06-7918com. Epub 2007 Mar 23.
In the immune-privileged cornea, epithelial wounds heal rapidly with almost no scarring and, unlike in most other tissues, acute inflammation in the absence of infection is beneficial to healing. Molecular mechanisms, which account for this striking property, remain to be clearly defined, but they likely include autacoids that control leukocyte activation. Two prominent enzymes, 12/15-lipoxygenase (LOX), which generates antiinflammatory lipid autacoids, and heme-oxygenase (HO), which generates antioxidants and carbon monoxide, are highly expressed in human and mouse corneas. LXA4, an endogenous 12/15-LOX product, proved to be a potent inhibitor of exacerbated inflammation and significantly increased re-epithelialization in corneal wounds. In vivo deletion of 12/15-LOX correlated with exacerbated inflammation and impaired wound healing in 12/15-LOX(-/-) mice, a phenotype that was rescued by treatment with LXA4. More importantly, 12/15-LOX(-/-) mice demonstrated impaired induction of HO-1 in both acute and exacerbated inflammation. Topical LXA4 restored HO-1 expression in 12/15-LOX(-/-) mice and amplified HO-1 gene expression in human corneal epithelial cells. HO-2(-/-) mice, which fail to induce HO-1, also demonstrated exacerbated inflammation in response to injury, a phenotype that, notably, correlated with a 50% reduction in endogenous LXA4 formation. Collectively, results demonstrate a critical role for LXA4 in inflammatory/reparative responses and provide the first evidence that 12/15-LOX and HO systems function in concert to control inflammation.
在免疫赦免的角膜中,上皮伤口愈合迅速,几乎不留疤痕,并且与大多数其他组织不同,在没有感染的情况下,急性炎症对愈合有益。解释这种显著特性的分子机制仍有待明确界定,但它们可能包括控制白细胞激活的自分泌物质。两种重要的酶,即产生抗炎脂质自分泌物质的12/15-脂氧合酶(LOX)和产生抗氧化剂及一氧化碳的血红素加氧酶(HO),在人和小鼠角膜中高度表达。内源性12/15-LOX产物LXA4被证明是加剧炎症的有效抑制剂,并且能显著增加角膜伤口的再上皮化。在体内敲除12/15-LOX与12/15-LOX(-/-)小鼠炎症加剧和伤口愈合受损相关,LXA4治疗可挽救该表型。更重要的是,12/15-LOX(-/-)小鼠在急性和加剧炎症中均表现出HO-1诱导受损。局部应用LXA4可恢复12/15-LOX(-/-)小鼠的HO-1表达,并增强人角膜上皮细胞中HO-1基因的表达。无法诱导HO-1的HO-2(-/-)小鼠在受伤时也表现出炎症加剧,值得注意的是,该表型与内源性LXA4生成减少50%相关。总体而言,结果表明LXA4在炎症/修复反应中起关键作用,并提供了首个证据,即12/15-LOX和HO系统协同发挥作用以控制炎症。